lipo-prostaglandin E1

Lipo-PGE1 is a formulation of prostaglandin E1 (PGE1, also known as alprostadil) encapsulated in lipid microspheres (liposomes). This nanoliposome-based delivery system enhances the pharmacological effects and safety profile of PGE1. Lipo-PGE1 acts primarily as a potent vasodilator and antiplatelet agent by mimicking endogenous prostaglandins. It increases peripheral blood flow, improves microcirculation, reduces inflammation and oxidative stress, inhibits platelet aggregation, and protects against ischemia-reperfusion injury. Clinically, it is used for acute lower limb ischemia as an adjuvant to surgery to reduce perioperative mortality and major adverse limb events; for peripheral vascular disease secondary to connective tissue disorders; in the management of ductus-dependent congenital heart disease in neonates; and has been studied for prevention of restenosis after percutaneous coronary intervention (PCI) and protection against liver dysfunction during chemotherapy. Compared with conventional PGE1 formulations, Lipo-PGE1 achieves efficacy at lower doses with fewer or less severe adverse reactions[2][3][5][6][10].

Brand names

Eglandin

Other names

liposomal prostaglandin E1lipo-prostaglandin E1lipid microsphere PGE1